

15 June 2016

Australian Securities Exchange
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

Alcidion Develops Data Acquisition Technology for NEDA

Highlights:

- **Data Acquisition Technology developed for National Echo Database Australia.**
- **Collates several million echocardiograms into national database.**

Alcidion Group Limited (ASX:ALC) has developed a new technology in partnership with the National Echocardiography Database of Australia (NEDA). The technology extracts, normalises and amalgamates data from Echocardiography ("Echo") studies performed around Australia into a single, centralized cloud hosted database server. NEDA is headed up by internationally renowned cardiologist, Professor David Playford and the CEO of the Pulmonary Hypertension Society Australia and New Zealand Inc, Associate Professor Geoff Strange.

"The NEDA study will be the largest study of heart function in the world. The NEDA study will obtain detailed information on heart function obtained using heart ultrasound ("echocardiography") across Australia, to create a secure database matched against national mortality data. The NEDA study will improve our understanding of heart disease and the risks associated with it" commented Professor David Playford.

An important example of a disease being investigated by the NEDA study is pulmonary hypertension. Pulmonary hypertension is high blood pressure between the heart and lungs, and is common, dangerous and under-diagnosed. Echoes, when performed for investigation of breathlessness, are often the first test identifying Pulmonary hypertension. Pulmonary hypertension has many underlying causes, and finding and treating the cause has a major impact on symptoms and survival. The NEDA study aims to identify the risk of death for each form of Pulmonary hypertension, and to identify new ways of diagnosing the condition.

We estimate that the NEDA study will collect information from several million Echoes over the duration of the study, creating an extremely valuable research tool that will enable us to delve deeper into heart disease than has been possible previously. Previous studies have been much smaller, and have not been linked with risk of death.

To enable such a network of data collection, NEDA engaged Alcidion to develop software to extract the relevant Echo data. After obtaining human research ethics approval for NEDA, Alcidion has developed an intelligent and highly innovative, vendor neutral, data extraction tool that correctly identifies the relevant data, converts then transfers it to a central database, and processes it suitable for analysis. This tool can be customized to allow it to be installed in multiple sites simultaneously for continuous transfer of data.

ENDS

For further information, please contact:

Nathan Buzza, Executive Director
Ph: +61 (0) 488862222
Alcidion Corporation
nathan.buzza@alcidion.com

Ray Blight, Chief Executive Officer
Ph: +61 (08) 8208 4600
Alcidion Corporation
ray.blight@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publically listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Corporation 2016. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.